Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine

Annals of Pharmacotherapy

Volumn 40, Issue 3, 2006, Pages 567-570

  Sokolski, Kenneth N ^a   Brown, Brenda J ^b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Depression; Insomnia; Phenelzine; Quetiapine

Indexed keywords

AMFEBUTAMONE; DESIPRAMINE; DIPHENHYDRAMINE; FLUOXETINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; PSYCHOTROPIC AGENT; QUETIAPINE; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INSOMNIA; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; SEROTONIN SYNDROME; SLEEP DISORDER; TREATMENT FAILURE;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; PHENELZINE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 33645071565     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G416     Document Type: Article

References (21)

1. Weiner M. Risperidone plus a monoamine oxidase inhibitor for agitated depression crisis. J Clin Psychopharmacol 1996;16:460-1.
2. Stoll AL, Haura G. Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psychopharmacol 2000;20:495-6.
3. Bodkin JA, Siris SG, Vermanzohn PC, Hennen J, Cole JO. Double-blind placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry 2005;162:388-90.
4. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990;51: 222-5.
5. Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerve RL. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993;13:312-20.
6. Keltner N, Harris CP. Serotonin syndrome: a case of fatal SSRI/MAOI interaction. Perspect Psychiatr Care 1994;30:26-31.
7. Weiner LA, Smythe M, Cisek J. Serotonin syndrome secondary to phenelzine-venlafaxine interaction. Pharmacotherapy 1998;18:399-403.
8. Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry 2003;18:264-5.
9. Berman RM, Narasimhan M, Charney DS. Treatment-refractory depression: definitions and characteristics. Depress Anxiety 1997;5:154-64.
10. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 1996;19:371-86.
11. Remick RA, Froese C, Keller FD. Common side effects associated with monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:497-504.
12. Birkenhager TK, van den Broek WW, Mulder PG, Bruijn JA, Moleman P. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry 2004;65:1505-10.
13. Zetin M. Combined use of trazodone and phenelzine in depression: case report. J Clin Psychiatry 1984;45:182-3.
14. Nierenberg AA, Keck PE Jr. Management of monoamine oxidase inhibitor-associated insomnia with trazodone. J Clin Psychopharmacol 1989;9:42-5.
15. Jacobsen FM. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. J Clin Psychiatry 1990; 51:298-302.
16. Brubacher JR, Hoffman RS, Lurin MJ. Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet Hum Toxicol 1996;38:358-61.
17. 1A receptor agonism. Brain Res 2002;956:349-57.
18. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002;161:263-70.
19. Juri C, Chana P, Tapia J, Kunstmann C, Parrao T. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol 2005;28:185-7.
20. Fernando A, Chew G. Chronic insomnia secondary to chronic pain responding to quetiapine (letter). Australas Psychiatry 2005;13:86.
21. Cohrs S, Rodenbeck A, Guan Z, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl) 2004;174:421-9.